Advertisement

Long-Term Comparative Outcomes of Patients With Peripheral Artery Disease With and Without Concomitant Coronary Artery Disease

Published:January 25, 2017DOI:https://doi.org/10.1016/j.amjcard.2016.12.023
      There are limited contemporary data on guideline-directed medical therapy (GDMT) utilization and long-term clinical outcomes in patients with peripheral artery disease (PAD) with and without concomitant coronary artery disease (CAD). From 2006 to 2013, 879 patients with claudication or critical limb ischemia (CLI) underwent diagnostic angiography or therapeutic endovascular intervention at our multidisciplinary vascular center. GDMT use was assessed at the time of angiography, and major adverse cardiovascular and cerebrovascular events (MACCE) and all-cause mortality were determined during 5 years of follow-up. Cox proportional hazard modeling was used to adjust for baseline differences between patients with and without concomitant CAD. Despite a higher adherence to GDMT (all p ≤0.002) for the use of aspirin, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, and statins, patients with PAD and concomitant CAD had higher unadjusted 5-year rates of MACCE (hazard ratio [HR] 1.7, 95% CI 1.3 to 2.1, p = 0.0001) and all-cause mortality (HR 1.86, 95% CI 1.4 to 2.4, p = 0.0001). After adjustment for baseline co-morbidities, the presence of CAD remained an independent risk factor for mortality (adjusted HR 1.35, 95% CI 1.02 to 1.80, p = 0.04) but not for MACCE (adjusted HR 1.24, 95% CI 0.96 to 1.60, p = 0.10) in patients with PAD. A sensitivity analysis limited to patients with CLI demonstrated that concomitant CAD was associated with significantly higher adjusted rates of both MACCE (adjusted HR 1.52, 95% CI 1.14 to 2.03, p = 0.01) and mortality (adjusted HR 1.64, 95% CI 1.12 to 2.20, p = 0.006). In conclusion, despite higher rates of GDMT use, PAD patients with concomitant CAD had significantly increased risk of all-cause mortality during a 5-year postprocedural follow-up. The subgroup of CLI patients with concomitant CAD was at particularly high risk for both MACCE and all-cause mortality.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Subherwal S.
        • Patel M.R.
        • Kober L.
        • Peterson E.D.
        • Bhatt D.L.
        • Gislason G.H.
        • Olsen A.-M.S.
        • Jones W.S.
        • Torp-Pedersen C.
        • Fosbol E.L.
        Peripheral artery disease is a coronary heart disease risk equivalent among both men and women: results from a nationwide study.
        Eur J Prev Cardiol. 2015; 22: 317-325
        • Steg P.G.
        • Bhatt D.L.
        • Wilson P.W.F.
        • D'Agostino R.
        • Ohman E.M.
        • Röther J.
        • Liau C.-S.
        • Hirsch A.T.
        • Mas J.-L.
        • Ikeda Y.
        • Pencina M.J.
        • Goto S.
        • REACH Registry Investigators
        One-year cardiovascular event rates in outpatients with atherothrombosis.
        JAMA. 2007; 297: 1197-1206
        • McDermott M.M.
        • Mehta S.
        • Ahn H.
        • Greenland P.
        Atherosclerotic risk factors are less intensively treated in patients with peripheral arterial disease than in patients with coronary artery disease.
        J Gen Intern Med. 1997; 12: 209-215
        • Mahoney E.M.
        • Wang K.
        • Keo H.H.
        • Duval S.
        • Smolderen K.G.
        • Cohen D.J.
        • Steg G.
        • Bhatt D.L.
        • Hirsch A.T.
        • on behalf of the Reduction of Atherothrombosis for Continued Health (REACH) Registry Investigators
        Vascular hospitalization rates and costs in patients with peripheral artery disease in the United States.
        Circ Cardiovasc Qual Outcomes. 2010; 3: 642-651
        • Pereg D.
        • Elis A.
        • Neuman Y.
        • Mosseri M.
        • Segev D.
        • Granek-Catarivas M.
        • Lishner M.
        • Hermoni D.
        Comparison of mortality in patients with coronary or peripheral artery disease following the first vascular intervention.
        Coron Artery Dis. 2014; 25: 79-82
        • Rooke T.W.
        • Hirsch A.T.
        • Misra S.
        • Sidawy A.N.
        • Beckman J.A.
        • Findeiss L.K.
        • Golzarian J.
        • Gornik H.L.
        • Halperin J.L.
        • Jaff M.R.
        • Moneta G.L.
        • Olin J.W.
        • Stanley J.C.
        • White C.J.
        • White J.V.
        • Zierler R.E.
        2011 ACCF/AHA focused update of the guideline for the management of patients with peripheral artery disease (updating the 2005 guideline) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
        Circulation. 2011; 124: 2020-2045
        • Hirsch A.T.
        • Haskal Z.J.
        • Hertzer N.R.
        • Bakal C.W.
        • Creager M.A.
        • Halperin J.L.
        • Hiratzka L.F.
        • Murphy W.R.C.
        • Olin J.W.
        • Puschett J.B.
        • Rosenfield K.A.
        • Sacks D.
        • Stanley J.C.
        • Taylor L.M.
        • White C.J.
        • White J.
        • White R.A.
        ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic) a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery,* Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (writing committee to develop guidelines for the management of patients with peripheral arterial disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation.
        Circulation. 2006; 113: e463-e654
        • Smith S.C.
        • Benjamin E.J.
        • Bonow R.O.
        • Braun L.T.
        • Creager M.A.
        • Franklin B.A.
        • Gibbons R.J.
        • Grundy S.M.
        • Hiratzka L.F.
        • Jones D.W.
        • Lloyd-Jones D.M.
        • Minissian M.
        • Mosca L.
        • Peterson E.D.
        • Sacco R.L.
        • Spertus J.
        • Stein J.H.
        • Taubert K.A.
        AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association.
        J Am Coll Cardiol. 2011; 58: 2432-2446
        • Pande R.L.
        • Perlstein T.S.
        • Beckman J.A.
        • Creager M.A.
        Secondary prevention and mortality in peripheral artery disease: National Health and Nutrition Examination Study, 1999 to 2004.
        Circulation. 2011; 124: 17-23
        • Hirsch A.T.
        • Hiatt W.R.
        • PARTNERS Steering Committee
        PAD awareness, risk, and treatment: new resources for survival–the USA PARTNERS program.
        Vasc Med Lond Engl. 2001; 6: 9-12
        • Subherwal S.
        • Patel M.R.
        • Kober L.
        • Peterson E.D.
        • Jones W.S.
        • Gislason G.H.
        • Berger J.
        • Torp-Pedersen C.
        • Fosbol E.L.
        Missed opportunities: despite improvement in use of cardioprotective medications among patients with lower-extremity peripheral artery disease, underuse remains.
        Circulation. 2012; 126: 1345-1354
        • Rodriguez F.
        • Cannon C.P.
        • Steg P.G.
        • Kumbhani D.J.
        • Goto S.
        • Smith S.C.
        • Eagle K.A.
        • Ohman E.M.
        • Umez-Eronini A.A.
        • Hoffman E.
        • Bhatt D.L.
        REACH registry investigators. Predictors of long-term adherence to evidence-based cardiovascular disease medications in outpatients with stable atherothrombotic disease: findings from the REACH registry.
        Clin Cardiol. 2013; 36: 721-727
        • Suarez C.
        • Zeymer U.
        • Limbourg T.
        • Baumgartner I.
        • Cacoub P.
        • Poldermans D.
        • Rother J.
        • Bhatt D.L.
        • Steg P.G.
        • REACH Registry Investigators
        Influence of polyvascular disease on cardiovascular event rates. Insights from the REACH registry.
        Vasc Med. 2010; 15: 259-265
        • McCoach C.E.
        • Armstrong E.J.
        • Singh S.
        • Javed U.
        • Anderson D.
        • Yeo K.K.
        • Westin G.G.
        • Hedayati N.
        • Amsterdam E.A.
        • Laird J.R.
        Gender-related variation in the clinical presentation and outcomes of critical limb ischemia.
        Vasc Med. 2013; 18: 19-26
        • Armstrong E.J.
        • Chen D.C.
        • Westin G.G.
        • Singh S.
        • McCoach C.E.
        • Bang H.
        • Yeo K.-K.
        • Anderson D.
        • Amsterdam E.A.
        • Laird J.R.
        Adherence to guideline-recommended therapy is associated with decreased major adverse cardiovascular events and major adverse limb events among patients with peripheral arterial disease.
        J Am Heart Assoc. 2014; 3: e000697
        • Armstrong E.J.
        • Chen D.C.
        • Singh G.D.
        • Amsterdam E.A.
        • Laird J.R.
        Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use is associated with reduced major adverse cardiovascular events among patients with critical limb ischemia.
        Vasc Med. 2015; 20: 237-244
        • Westin G.G.
        • Armstrong E.J.
        • Bang H.
        • Yeo K.-K.
        • Anderson D.
        • Dawson D.L.
        • Pevec W.C.
        • Amsterdam E.A.
        • Laird J.R.
        Association between statin medications and mortality, major adverse cardiovascular event, and amputation-free survival in patients with critical limb ischemia.
        J Am Coll Cardiol. 2014; 63: 682-690
        • Armstrong E.J.
        • Anderson D.R.
        • Yeo K.-K.
        • Singh G.D.
        • Bang H.
        • Amsterdam E.A.
        • Freischlag J.A.
        • Laird J.R.
        Association of dual-antiplatelet therapy with reduced major adverse cardiovascular events in patients with symptomatic peripheral arterial disease.
        J Vasc Surg. 2015; 62: 157-165.e1
        • Hertzer N.R.
        • Beven E.G.
        • Young J.R.
        • O'Hara P.J.
        • Ruschhaupt W.F.
        • Graor R.A.
        • Dewolfe V.G.
        • Maljovec L.C.
        Coronary artery disease in peripheral vascular patients. A classification of 1000 coronary angiograms and results of surgical management.
        Ann Surg. 1984; 199: 223-233
        • Bhatt D.L.
        Diffuse coronary disease and atherothrombosis: a rationale for long-term therapy to prevent recurrent ischemic events.
        J Invasive Cardiol. 2003; 15 (discussion 9B–10B): 3B-9B
        • Bhatt D.L.
        • Eagle K.A.
        • Ohman E.M.
        • Hirsch A.T.
        • Goto S.
        • Mahoney E.M.
        • Wilson P.W.F.
        • Alberts M.J.
        • D'Agostino R.
        • Liau C.-S.
        • Mas J.-L.
        • Röther J.
        • Smith S.C.
        • Salette G.
        • Contant C.F.
        • Massaro J.M.
        • Steg P.G.
        • REACH Registry Investigators
        Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis.
        JAMA. 2010; 304: 1350
        • Feringa H.H.H.
        • van Waning V.H.
        • Bax J.J.
        • Elhendy A.
        • Boersma E.
        • Schouten O.
        • Galal W.
        • Vidakovic R.V.
        • Tangelder M.J.
        • Poldermans D.
        Cardioprotective medication is associated with improved survival in patients with peripheral arterial disease.
        J Am Coll Cardiol. 2006; 47: 1182-1187
        • Antithrombotic Trialists' Collaboration
        Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
        BMJ. 2002; 324: 71-86
        • Heart Protection Study Collaborative Group
        MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.
        Lancet. 2002; 360: 7-22
        • Yusuf S.
        • Sleight P.
        • Pogue J.
        • Bosch J.
        • Davies R.
        • Dagenais G.
        Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators.
        N Engl J Med. 2000; 342: 145-153
        • Gerhard-Herman M.D.
        • Gornik H.L.
        • Barrett C.
        • Barshes N.R.
        • Corriere M.A.
        • Drachman D.E.
        • Fleisher L.A.
        • Fowkes F.G.R.
        • Hamburg N.M.
        • Kinlay S.
        • Lookstein R.
        • Misra S.
        • Mureebe L.
        • Olin J.W.
        • Patel R.A.G.
        • Regensteiner J.G.
        • Schanzer A.
        • Shishehbor M.H.
        • Stewart K.J.
        • Treat-Jacobson D.
        • Walsh M.E.
        2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
        Circulation. 2016; ([Epub ahead of print])
        • Fowkes F.G.R.
        • Low L.-P.
        • Tuta S.
        • Kozak J.
        • AGATHA Investigators
        Ankle-brachial index and extent of atherothrombosis in 8891 patients with or at risk of vascular disease: results of the international AGATHA study.
        Eur Heart J. 2006; 27: 1861-1867